Stephan Lab

CREATING LIVING DRUGS WITH SYNTHETIC COMPOUNDS

 

 
 
Screen Shot 2021-01-14 at 1.52.24 PM.png
 
Screen Shot 2020-02-19 at 9.27.10 AM.jpg

Nature Biomedical Engineering, VOL 4, February 2020, 195-206

https://www.nature.com/articles/s41551-019-0486-0

 
Nat Commun. 2019 Sep 3;10(1):3974. doi: 10.1038/s41467-019-11911-5.

Nat Commun. 2019 Sep 3;10(1):3974. doi: 10.1038/s41467-019-11911-5.

 
Fan Zhang, Sirkka B. Stephan, Chibawanye I. Ene, Tyrel T. Smith, Eric C. Holland and Matthias T. Stephan. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies. Cancer Research. Ju…

Fan Zhang, Sirkka B. Stephan, Chibawanye I. Ene, Tyrel T. Smith, Eric C. Holland and Matthias T. Stephan. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies. Cancer Research. July 2018.

Attack of the killer clones. The next generation of modified T-cell therapies is taking on solid tumors - but it's an uphill fight. Nature. 20 December 2017

Attack of the killer clones. The next generation of modified T-cell therapies is taking on solid tumors - but it's an uphill fight. Nature. 20 December 2017

Howell F. Moffett, Michael E. Coon, Stefan Radtke, Sirkka B. Stephan, Laura McKnight. Abigail Lambert, Barry L. Stoddard, Hans-Peter Kiem & Matthias T. Stephan. Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. Nature Communications.  8, Article number: 389 (2017). 

http://rdcu.be/vpnP

Tyrel T. Smith, Sirkka B. Stephan, Howell F. Moffett, Laura E. McKnight, Weihang Ji, Diana Reiman, Emmy Bonagofski, Martin E. Wohlfahrt, Smitha P. S. Pillai & Matthias T. Stephan. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nature Nanotechnology. 2017 Aug: 813-820.

http://www.nature.com/nnano/journal/v12/n8/full/nnano.2017.57.html

Smith TT, Moffett HF, Stephan SB, Opel CF, Dumigan AG, Jiang X, Pillarisetty VG, Pillai SPS, Wittrup KD, Stephan MT. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumor. Journal of Clinical Investigation. 2017 Jun 1;127(6):2176-2191.

http://www.jci.org/articles/view/87624.html

 

Sirkka B. Stephan, Alexandria M. Taber, Ilona Jileaeva, Ericka P. Pegues, Charles L. Sentman and Matthias T. Stephan. Biopolymer implants enhance the efficacy of adoptive T cell therapy. Nature Biotechnology. 33, 97-101 (2015).

http://www.nature.com/nbt/journal/v33/n1/full/nbt.3104.html

 

 

Matthias T. Stephan, Straight Shooters: Peptibodies Takes Aim.

Sci Transl Med 11 June 2014: Vol. 6, Issue 240, p. 240ec102

http://stm.sciencemag.org/content/6/240/240ec102

(Editor’s Choice article on Qin et al., Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine. published online 25 May 2014).

 

Matthias T. Stephan, Carbon Nanotubes Are Picky Hitchhikers.

Sci Transl Med 30 April 2014: Vol. 6, Issue 234, p. 234ec77

http://stm.sciencemag.org/content/6/234/234ec77

(Editor’s Choice article on B. R. Smith et al., Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat. Nanotechnol., published online 13 April 2014).


.